CHICAGO, IL - Long Grove Pharmaceuticals, LLC, a manufacturer of differentiated pharmaceuticals, is expanding its product offerings through a strategic in-licensing of Cyclophosphamide for Injection, USP from Sunny Pharmtech, Inc. Cyclophosphamide for Injection, USP will be manufactured by Sunny Pharmtech, Inc. in Taiwan. The product is an APrated generic product and Trade Agreement Act (TAA) compliant. 

Cyclophosphamide for Injection, USP is an antineoplastic chemotherapy medication that slows the growth of cancer cells. It is used to treat multiple malignant diseases, including blood cancers and solid tumors. Sunny Pharmtech, Inc. received Food and Drug Administration (FDA) approval for the drug through an Abbreviated New Drug Application (ANDA) in October 2023. It is currently available in 500 milligram, 1 gram and 2 gram dry powder vials. 

“Our team at Long Grove Pharmaceuticals has a long history of collaboration with Sunny Pharmtech, Inc,” said Peter Karas, Chief Commercial Officer at Long Grove Pharmaceuticals. “This current opportunity to jointly offer cyclophosphamide continues our commitment to improving customer choice by increasing access to generics.” 

“Our partnership with Long Grove Pharmaceuticals helps ensure we can successfully bring cyclophosphamide to market in the U.S.,” said Yon-Lian Wu, Ph.D., Founder, Chairman and Chief Executive Officer at Sunny Pharmtech, Inc. “We’re excited about the launch of cyclophosphamide, but also by the continued opportunity to collaborate on pharmaceutical products that save and improve lives.” 

For more information about Long Grove Pharmaceuticals and Cyclophosphamide for Injection, USP, visit www.longgrovepharma.com.